JP2018528948A5 - - Google Patents

Download PDF

Info

Publication number
JP2018528948A5
JP2018528948A5 JP2018510724A JP2018510724A JP2018528948A5 JP 2018528948 A5 JP2018528948 A5 JP 2018528948A5 JP 2018510724 A JP2018510724 A JP 2018510724A JP 2018510724 A JP2018510724 A JP 2018510724A JP 2018528948 A5 JP2018528948 A5 JP 2018528948A5
Authority
JP
Japan
Prior art keywords
apremilast
toluene
mixture
acetic acid
isolated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018510724A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018528948A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/SG2016/050413 external-priority patent/WO2017039537A1/en
Publication of JP2018528948A publication Critical patent/JP2018528948A/ja
Publication of JP2018528948A5 publication Critical patent/JP2018528948A5/ja
Pending legal-status Critical Current

Links

JP2018510724A 2015-08-28 2016-08-25 アプレミラストの新規形態及びその作成方法 Pending JP2018528948A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562211280P 2015-08-28 2015-08-28
US62/211,280 2015-08-28
US201662279147P 2016-01-15 2016-01-15
US62/279,147 2016-01-15
PCT/SG2016/050413 WO2017039537A1 (en) 2015-08-28 2016-08-25 Novel forms of apremilast and the process of making the same

Publications (2)

Publication Number Publication Date
JP2018528948A JP2018528948A (ja) 2018-10-04
JP2018528948A5 true JP2018528948A5 (enExample) 2019-08-29

Family

ID=58097541

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018510724A Pending JP2018528948A (ja) 2015-08-28 2016-08-25 アプレミラストの新規形態及びその作成方法

Country Status (9)

Country Link
US (1) US9765026B2 (enExample)
EP (1) EP3341360A4 (enExample)
JP (1) JP2018528948A (enExample)
KR (1) KR20180036791A (enExample)
CN (1) CN107922332A (enExample)
CA (1) CA2994217A1 (enExample)
IL (1) IL257195A (enExample)
TW (1) TWI613191B (enExample)
WO (1) WO2017039537A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016174685A1 (en) * 2015-04-27 2016-11-03 Mylan Laboratories Limited Process for the enantiomeric resolution of apremilast intermediates
US10544097B2 (en) * 2015-08-27 2020-01-28 Msn Laboratories Private Limited Solid state forms of N-[2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]acetamide and process for preparation thereof
CN106977444B (zh) * 2016-01-18 2021-10-08 重庆医药工业研究院有限责任公司 一种阿普斯特无定型的制备方法
EA038882B1 (ru) * 2016-03-30 2021-11-02 Сарудбхава Формулатионс Приват Лимитед Фармацевтическая композиция апремиласта
CN107686461A (zh) * 2016-08-04 2018-02-13 广东东阳光药业有限公司 阿普斯特的溶剂化物及其制备方法和用途
WO2019021303A1 (en) * 2017-07-23 2019-01-31 Alkem Laboratories Limited NOVEL PROCESS FOR THE PREPARATION OF APREMILAST IN AMORPHOUS FORM
CN108440381A (zh) * 2018-03-15 2018-08-24 威海迪素制药有限公司 一种阿普斯特新晶型h及其制备方法
AR125097A1 (es) 2021-04-26 2023-06-07 Amgen Inc Proceso para la síntesis de apremilast
WO2023120466A1 (ja) * 2021-12-23 2023-06-29 沢井製薬株式会社 アプレミラスト水和物含有製剤

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8093293B2 (en) 1998-07-06 2012-01-10 Johnson & Johnson Consumer Companies, Inc. Methods for treating skin conditions
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US8796313B2 (en) * 2005-11-01 2014-08-05 Janssen Pharmaceutica N.V. Substituted dihydroisoindolones as allosteric modulators of glucokinase
PL2276483T3 (pl) * 2008-03-27 2014-09-30 Celgene Corp Stałe postacie zawierające (+)-2-[1-(3-etoksy-4-metoksyfenylo)-2-metylosulfonyloetylo]-4-acetyloaminoizoindolino-1,3-dion, kompozycje je zawierające i ich zastosowania
CN108059635B (zh) * 2009-05-14 2021-10-01 天津合美医药科技有限公司 噻吩衍生物
EP2723717A2 (en) * 2011-06-24 2014-04-30 Amgen Inc. Trpm8 antagonists and their use in treatments
US8981117B2 (en) 2012-09-14 2015-03-17 Celgene Corporation Processes for the preparation of isoindole compounds and isotopologues thereof
UY35103A (es) * 2012-10-29 2014-05-30 Glaxo Group Ltd Compuestos de cefem 2-sustituidos
EP2730278A1 (en) * 2012-11-08 2014-05-14 Ratiopharm GmbH Composition melt
IN2014MU01283A (enExample) 2014-04-04 2015-10-09 Cadila Healthcare Ltd
CN104447445B (zh) 2014-12-05 2016-07-06 新发药业有限公司 一种合成阿普斯特中间体的制备方法
US10377712B2 (en) 2015-05-26 2019-08-13 Lupin Limited Process for preparation of apremilast and novel polymorphs thereof
WO2016199031A1 (en) * 2015-06-09 2016-12-15 Dr. Reddy’S Laboratories Limited Process for preparation of apremilast and its intermediates

Similar Documents

Publication Publication Date Title
JP2018528948A5 (enExample)
WO2016065209A3 (en) Process for the preparation of (r,s)-nicotine
JP2008235603A5 (enExample)
JP2014534287A5 (enExample)
JP2016535744A5 (enExample)
JP2018507858A5 (enExample)
CN110114472A (zh) 将线性测序文库转换为环状测序文库的方法
JP2012001634A5 (enExample)
JP2018509457A5 (enExample)
JP2015532666A5 (enExample)
RU2017101808A (ru) Способы получения 1, 3-бензодиоксольных гетероциклических соединений
RU2011154176A (ru) Способ получения 6-(арил)-4-аминопиколинатов
JP2014534985A5 (enExample)
JP2018518008A5 (enExample)
JP2015183178A5 (enExample)
JP2015518469A5 (enExample)
JP2018009003A5 (enExample)
JP2018534942A5 (enExample)
JP2010205731A5 (enExample)
JP2017517513A5 (enExample)
JP2015129927A5 (enExample)
JP2015536305A5 (enExample)
JP2012255133A5 (enExample)
WO2016104960A3 (ko) 결정성 페북소스타트 피돌레이트 염 및 이의 제조 방법
JP2016520122A5 (enExample)